We observed that etoposide (10 nM), etomoxir (5 μM) and thioridazine (10 μM), but not mildronate (1 mmol/L), was able to significantly reduce the production of IL-6 (P = 0.0022 for etoposide and thioridazine and P = 0.0476 for etomoxir), in PMBCs from SSc patients (Figure 4B). This evidence concerns the gene IL6 and systemic sclerosis.